浙江海利得新材料股份有限公司投资设立全资子公司重大公告解读

重要公告摘要

• 公司证券代码：002206，证券简称：海利得
• 公告编号：2026-013
• 董事会会议时间：2026年3月30日
• 会议通知发出时间：2026年3月24日
• 第九届董事会第八次会议全体董事出席，无缺席
• 会议由董事长高王伟先生主持
• 会议程序符合《公司法》和《公司章程》相关规定

投资决议及详细内容

• 会议审议并全票通过《关于投资设立全资子公司的议案》
• 公司拟以自有资金5,000万元设立全资子公司，暂定名为“浙江海利得医疗科技有限公司”（最终以工商核准登记为准）
• 设立新公司主要是基于公司战略规划及未来业务发展需求，表明公司有意拓展医疗科技领域业务
• 此次投资决策权属于董事会权限范围，无需股东大会批准
• 本次投资不涉及关联交易，不构成重大资产重组
• 相关公告已在《证券时报》及巨潮资讯网同步披露

对股东与投资者的影响

• 公司进军医疗科技领域，可能带来新的业务增长点，提升公司未来盈利能力和市场竞争力
• 此举可能会吸引市场关注，提升公司估值预期，对股价产生积极影响
• 全票通过显示董事会一致认可该战略举措，表明公司管理层对未来发展充满信心
• 投资金额较大（5,000万元），但采用自有资金，未涉及外部融资或债务压力
• 此次事项无需股东大会批准，决策效率高，预示公司未来或有更多战略性业务调整动作

投资设立全资子公司细节

• 新子公司名称暂定为“浙江海利得医疗科技有限公司”
• 资金来源为公司自有资金
• 资料显示公司正积极布局医疗科技领域，或将带来业务多元化和风险分散
• 公司承诺信息披露真实、准确、完整，无虚假记载或重大遗漏

结论与展望

海利得新材料股份有限公司本次投资设立全资子公司，进军医疗科技行业，是公司战略升级的重要一步，预计将增强公司未来业务结构和盈利能力。此举对于投资者而言具有高度关注价值，属潜在影响股价的重大事项。建议投资者持续关注后续进展及公司在医疗科技领域的具体布局与成果。

免责声明：本文仅为信息解读，不构成投资建议。市场风险需谨慎，投资者请根据自身情况合理决策。

English Version

Zhejiang Hailide New Material Co., Ltd. Announces Investment in Wholly-Owned Subsidiary: Detailed Analysis

Key Points of the Announcement

• Stock Code: 002206, Stock Name: Hailide
• Announcement No.: 2026-013
• Board Meeting Date: March 30, 2026
• Notice Sent: March 24, 2026
• All seven directors attended the 8th meeting of the 9th Board; no absentees
• Meeting chaired by Chairman Mr. Gao Wangwei
• Meeting procedures complied with Company Law and Articles of Association

Investment Decision and Details

• The board unanimously approved the proposal to invest in establishing a wholly-owned subsidiary
• The company plans to invest RMB 50 million of its own funds to establish a wholly-owned subsidiary, tentatively named “Zhejiang Hailide Medical Technology Co., Ltd.” (final name subject to industrial and commercial registration)
• Establishment of the new subsidiary aligns with the company’s strategic planning and future business development needs, indicating a move into the medical technology sector
• This investment falls within the board’s authority and does not require shareholder approval
• The investment does not involve related-party transactions and does not constitute a major asset restructuring
• Further details are disclosed in the Securities Times and CNINFO

Implications for Shareholders and Investors

• The company’s entry into the medical technology field may provide new growth drivers, enhance future profitability, and strengthen market competitiveness
• This move may attract market attention and raise valuation expectations, potentially impacting share price positively
• Unanimous board approval signals strong confidence from management in this strategic step
• The investment amount is significant (RMB 50 million), but funded by company’s own resources, with no external financing or debt pressure
• No shareholder meeting required, indicating high decision-making efficiency and possibly more strategic adjustments in the future

Details of Subsidiary Establishment

• The new subsidiary is tentatively named “Zhejiang Hailide Medical Technology Co., Ltd.”
• Funding source: company’s own funds
• The company is actively expanding into medical technology, which will diversify business and mitigate risks
• The company guarantees full, accurate, and truthful disclosure with no false or misleading statements

Conclusion & Outlook

Zhejiang Hailide New Material Co., Ltd.’s investment in a wholly-owned subsidiary marks a significant strategic upgrade and entry into the medical technology sector. This is a major event for investors, with potential to impact share price. Investors are advised to closely monitor future developments and the company’s progress in medical technology.

Disclaimer: This article is for information analysis only and does not constitute investment advice. Please assess risks carefully and make decisions based on your own situation.

View 海 利 得 Historical chart here